Endometrial cancer
Conditions
Interventions
single group:sintilimab combined with bevacizumab
Sponsors
Foshan First People's Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Metastatic or locally advanced unresectable endometrial carcinoma in women aged 18 and over; 2. Patients have tumor specimens (formalin fixed, paraffin embedded or fresh pretreated recurrent tumor tissue), which can be used to detect the expression of PD-L1; 3. Radiotherapy and chemotherapy are allowed for neoadjuvant or adjuvant stage 4. According to the recurrence and metastasis, patients can accept the progress of first-line chemotherapy or patients are intolerant to chemotherapy; 5. At least one measurable lesion; 6. ECoG PS: 0-1 point; 7. Estimated survival >= 12 weeks; 8. No serious damage to bone marrow, liver and kidney function; 9. Women of childbearing age without hysterectomy must have taken reliable contraceptive measures, or have conducted pregnancy test (serum or urine) within 7 days before enrollment, and the result is negative, and are willing to use appropriate contraceptive methods during the test and 8 weeks after the last administration of the test drug; 10. The subjects volunteered to join the study, with good compliance and follow-up.
Exclusion criteria
Exclusion criteria: 1. Previously received second-line or above systematic treatment for advanced endometrial cancer; 2.Untreated central nervous system diseases (patients with asymptomatic central nervous system metastasis are allowed); 3. Previous history of autoimmune diseases; 4.Antibody positive for acute or chronic active hepatitis B or acute or chronic active hepatitis C; 5. Have been treated with immune checkpoint inhibitors; 6. Received systemic glucocorticoid or immunosuppressive therapy in the last 4 weeks; 7. Any serious underlying disease, complications and active infection; 8. Receiving other anti-tumor treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression-free survival time;overall survival time;objective response rate; | — |
Countries
China
Contacts
Public ContactXie Yong
Foshan First People's Hospital
Outcome results
None listed